What is the ICD-10 (International Classification of Diseases, 10th Revision) code for blue skin discoloration caused by Minocycline (Minocycline hydrochloride)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The ICD-10 code for blue skin discoloration caused by Minocycline (Minocycline hydrochloride) is L81.8, which represents "Other specified disorders of pigmentation". This code is used when documenting hyperpigmentation resulting from medication use, including the blue-gray discoloration that can occur with long-term Minocycline therapy, as noted in the guidelines of care for the management of acne vulgaris 1. Minocycline-induced pigmentation typically appears as blue-gray patches on sun-exposed areas, scars, or areas of inflammation. This side effect results from the deposition of drug metabolites or iron complexes in the skin tissues. The discoloration may persist for months to years after discontinuation of the medication.

When documenting this condition, it's essential to also code the underlying reason for Minocycline use and note that the skin change is an adverse effect of the medication using an additional code (T36.8X5A for adverse effect of other systemic antibiotics, initial encounter) 1. This helps establish the causal relationship between the medication and the skin manifestation. Key points to consider include:

  • The condition is a result of Minocycline use, which is often prescribed for moderate to severe inflammatory acne 1.
  • The skin discoloration can be a significant concern for patients, affecting their quality of life.
  • Accurate coding is crucial for medical records and insurance purposes, ensuring that patients receive appropriate care and compensation for medication-related adverse effects.

Given the potential for significant morbidity associated with Minocycline-induced skin discoloration, including its impact on quality of life, it is crucial to document this condition accurately using the ICD-10 code L81.8. This coding practice supports comprehensive patient care and facilitates further research into the adverse effects of Minocycline and other medications 1.

From the Research

ICD-10 Code for Blue Skin Discoloration

The ICD-10 code for blue skin discoloration caused by Minocycline is not explicitly stated in the provided studies. However, the studies describe the condition as a form of hyperpigmentation or pigmentation disorder.

Types of Minocycline-Induced Hyperpigmentation

  • Type I: blue-black pigmentation confined to sites of scarring or inflammation on the face 2
  • Type II: blue-grey circumscribed pigmentation of normal skin of the lower legs and forearms 2
  • Type III: diffuse muddy brown pigmentation of normal skin accentuated in sun-exposed areas 2, 3
  • A fourth type of minocycline-induced cutaneous pigmentation has also been described, characterized by circumscribed blue-grey pigmentation within acne scars confined to the back 2

Characteristics of Minocycline-Induced Hyperpigmentation

  • The pigmentation can appear at multiple sites, including the skin, nails, bones, thyroid, mouth, and eyes 4
  • The discoloration can vary from blue, slate-gray, or brown, and typically occurs in a dose-dependent fashion 5
  • The mechanism of hyperpigmentation remains largely unknown 5

Diagnosis and Management

  • Minocycline-induced pigmentation is generally reversible when the drug is discontinued, although the pigmentation can be permanent in some cases 4
  • Patients receiving minocycline, especially those treated for longer than 1 year, require screening for the development of pigmentation 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A new type of minocycline-induced cutaneous hyperpigmentation.

Clinical and experimental dermatology, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.